European VC Funds

1984 Ventures, founded in 2018 and based in San Francisco, is a venture capital firm focusing on seed and early-stage investments in software businesses. The firm targets sectors such as fintech, healthcare, SaaS, e-commerce, and consumer technology. Their portfolio includes notable companies like Properly, Brace, and Heroes Jobs​. The firm has made 120 investments, with 9 successful exits to date, including Convex, which was acquired in 2024. 1984 Ventures has recently invested in companies like Fay, Collaborative Robotics, and Alaffia Health in 2024​. 1984 Ventures is led by founder and managing partner Ramy Adeeb, and they leverage their entrepreneurial experience to help portfolio companies grow. They emphasize supporting startups that apply technology to solve real-world problems​.

2048 Ventures is a venture capital firm founded in 2018 and headquartered in New York, NY. The firm focuses on early-stage investments, particularly in technology-driven startups. They have a strong portfolio with over 120 investments across diverse sectors, including biotechnology, artificial intelligence, health tech, and commercial products. Some notable companies backed by 2048 Ventures include Adaptis Technologies, an AI-powered platform for optimizing the carbon footprint of buildings, and Fathom Optics, which delivers 3D experiences using standard printing technologies. Their investment strategy is to support visionary founders at the earliest stages, often leading pre-seed and seed rounds. 2048 Ventures has shown significant activity, with their portfolio companies collectively raising $591 million and reaching a valuation of $2.6 billion by the end of 2023. They have invested in innovative companies like TwoStep Therapeutics, which specializes in modular peptide technology for targeting solid tumors, and Century Health, which leverages AI to accelerate drug development​.

2150 is a London, Copenhagen, and Berlin-based venture capital firm focused on transforming urban environments through sustainable technology. With a €268 million fund, 2150 invests in companies that address major challenges across the "Urban Stack"—everything from the design and construction of cities to how they are powered and maintained. Their mission is to support groundbreaking startups that can reimagine urban living, while significantly reducing carbon emissions and improving sustainability. 2150 primarily invests in Series A and B stage companies, with check sizes ranging from $1 million to $7 million. Their focus spans climate tech, green solutions, and innovative materials, all aimed at creating smarter, more efficient cities. The firm’s portfolio includes companies like CarbonCure, which injects recycled CO₂ into concrete to reduce its carbon footprint, Normative, a platform that helps businesses track and manage their carbon emissions, and Ampd Energy, which electrifies construction sites to minimize pollution. Beyond financial backing, 2150 takes a hands-on approach, working closely with founders to scale their businesses and maximize impact. The firm’s ultimate goal is to build a portfolio capable of mitigating gigatonnes of CO₂ emissions, comparable to the entire annual output of countries like Germany and France. With strong backing from investors like Novo Holdings and the BMW Foundation, 2150 is positioned as a key player in the future of urban development, driving both commercial success and global sustainability.

27V (Twenty Seven Ventures) is a venture capital firm that focuses on early-stage investments in EdTech (education technology) and Future of Work startups. The firm was founded by Atin Batra and is headquartered in the Cayman Islands. Since its inception in late 2019, 27V has invested in 28 companies across regions including North America, Europe, and Asia Pacific (excluding India and China). 27V typically invests at the pre-seed and seed stages, with initial checks ranging from $50,000 to $250,000, and reserves funds for follow-on investments. The firm is more than just a fund; it promotes a "Founder Fellowship" that emphasizes community and connections among founders and their teams, facilitating shared learning and support. Notable investments in their portfolio include companies like Fluent, which aims to revolutionize language learning, and Preteckt, which uses machine learning to predict maintenance issues in vehicles. 27V's unique approach includes a scout network that helps identify promising startups from underrepresented communities, fostering diversity and inclusion in the venture capital ecosystem.

2xN is a London-based, quantum-focused venture capital fund co-founded by Lars Fjeldsoe-Nielsen and Niels Nielsen. The firm specializes in early-stage investments, primarily targeting startups in quantum computing and other sectors with transformative potential like mobility, edtech, and marketplaces. Notable investments include quantum heavyweights Quantinuum and Kvantify, as well as StudySmarter, demonstrating its focus on impactful technologies. With a $120 million fund, 2xN typically invests $3 to $5 million in pre-seed to Series A rounds, actively backing companies across Europe and the U.S. The fund's strategy is highly collaborative, often co-investing with prominent VCs like Sequoia and A16Z, favoring founders with a vision for societal impact. Rather than dominating deals, 2xN aims to create network effects and long-term partnerships, making them a hands-on, founder-first investor. The team’s dual expertise—Nielsen’s pioneering work in quantum computing and Fjeldsoe-Nielsen’s background in Silicon Valley—enables them to offer deep, technical guidance while scaling businesses rapidly. Startups are encouraged to approach the fund with disruptive ideas in core sectors like quantum, as 2xN builds its deal flow through a strong network of repeat entrepreneurs and global investors.

360 Capital Partners is a prominent early-stage venture capital firm based in Europe, with offices in Paris and Milan. The firm invests from pre-seed to Series B stages, focusing on deep tech, climate tech, and digital-first solutions. They support startups that have the potential to disrupt traditional business models and drive technological innovation. The firm has a diverse portfolio of over 150 startups, with notable investments including Prophesee, Exotec, and Energy Dome. Their portfolio reflects a commitment to backing technologies that emerge from cutting-edge research and have the power to reshape entire industries. 360 Capital Partners also collaborates closely with institutions like Politecnico di Milano to accelerate technological advancements​. Geographically, 360 Capital Partners concentrates on Europe, leveraging a robust network and extensive expertise to help entrepreneurs scale their businesses to their full potential. The firm's strategy emphasizes sustainable technological progress, aligning investments with the global push for climate change solutions and the digital transformation of various sectors​. The team at 360 Capital Partners comprises experienced professionals such as Alessandro Zaccaria and Alexandre Mordacq, who bring valuable insights and strategic support to their portfolio companies. The firm's long-standing presence in the European VC ecosystem and its forward-thinking investment philosophy make it a key player in driving innovation and growth in the region​.

3B Ventures is an impact-driven venture capital firm founded in 2017 with headquarters in Copenhagen, Denmark. The fund primarily focuses on solving global challenges through investments in key sectors like agribusiness, clean-tech, energy, and healthcare. It has a global reach, with a particular focus on markets in Malaysia, Europe, and the United States. The firm targets early-stage startups and seed-stage companies that are developing innovative solutions with potential for significant impact. 3B Ventures has been involved in notable investments like AnaCardio, a biopharma company focused on medical advancements, where they participated in a substantial $18 million funding round. The fund’s average deal size is around $18 million, indicating that it takes a substantial approach to backing its portfolio companies. Founded by James Digby and Jan-Cayo Fiebig, 3B Ventures is committed to not only providing capital but also delivering strategic support to help companies scale and solve large-scale global problems. The firm tends to look for entrepreneurs passionate about creating change, with business models that align with their vision for a sustainable and impactful future. They prefer to work with founders who have a clear path to growth and profitability, and they actively engage in nurturing these businesses through their extensive network and resources. Entrepreneurs looking to approach 3B Ventures are encouraged to present well-developed solutions with demonstrable traction in key markets.

3LB Seed Capital is a venture capital firm based in Turin, Italy, focusing on early-stage investments in innovative startups, particularly those in Italy and the EU. The firm typically invests between €30k and €60k in startups, often becoming the first investor outside the founders' circle. For larger investments, up to €500k, they partner with other investors and syndicates. Their portfolio includes diverse sectors, with a notable balance between digital and hardware-focused companies. Key investments include Quantum Bridge in cybersecurity, Axelera AI in hardware and AI, NewCleo in climate tech, D-Orbit in space technology, and Anthropic in AI software. They have seen successful exits, including Electra Vehicles and Metis Precision Medicine. 3LB Seed Capital emphasizes a hands-on approach, providing strategic support and leveraging their network to help startups grow and raise additional capital. The firm aims to foster strong relationships with entrepreneurs, acting as business partners to support the development and success of their ventures.

3M Ventures, the corporate venture capital arm of 3M, focuses on investing in early-stage companies that align with 3M's strategic priorities. These priorities include automotive electrification, safety, home improvement, consumer electronics, climate tech, sustainable packaging, industrial automation, and semiconductor and data center technologies. Their investment strategy targets companies with strong intellectual property, demonstrated commercial traction, and robust management teams​. Notable investments by 3M Ventures include GrayMatter Robotics, Moxe Health, and Metalenz, which span across artificial intelligence, healthcare, and 3D technology, respectively. 3M Ventures seeks to not only provide financial investment but also leverage 3M's extensive technological platforms, manufacturing capabilities, and global networks to help scale their partner companies​. 3M is also heavily committed to sustainability. The company has pledged $1 billion to achieve carbon neutrality, reduce water use, and improve water quality by 2030. This initiative includes implementing state-of-the-art water purification technology and developing innovative solutions for renewable energy and emissions reduction​.

3VC is a European venture capital fund that focuses on investing in tech startups with global ambitions, primarily at the Series A stage. They are known for their hands-on support and strong partnerships with founders, offering not only capital but also strategic guidance and connections to help startups grow and succeed. Notable investments by 3VC include simpleclub, an education technology platform; Creatopy, a graphic design platform; Storyblok, a headless CMS platform; and Assaia, which provides AI solutions for airport ground operations. Their approach emphasizes understanding the specific markets their portfolio companies operate in, and they are known for their proactive support throughout the investment process. 3VC was co-founded by Peter Lasinger and Roman Scharf, who bring extensive entrepreneurial and investment experience. The firm is dedicated to investing responsibly and supporting the growth of their portfolio companies with a strong focus on quality partnerships and sustainable development

415 Capital is a Munich-based venture capital firm that specializes in investing in breakthrough medical technologies, particularly those addressing critical unmet needs in cardiovascular and neurovascular diseases. With a focus on improving patient outcomes and reducing healthcare costs, 415 Capital invests in startups across Europe, Israel, and North America, typically writing checks between €5 million and €15 million per company. The firm’s portfolio boasts several cutting-edge companies like Supira Medical, which is developing a percutaneous ventricular assist device for high-risk heart patients, and Distalmotion, known for its innovative surgical robotics platform. 415 Capital avoids biotech, healthcare services, and wellness products, honing in exclusively on medtech innovations. Their strategy emphasizes deep involvement from the R&D stage through commercialization, leveraging close relationships with healthcare providers and access to a €2 billion commercial channel in Europe. The firm’s team combines expertise in investment, medical device commercialization, and clinical practice, ensuring they remain at the forefront of medical innovation. Historically, 415 Capital has been part of significant advancements such as the development of transcatheter heart valves and renal denervation technologies. Their approach to venture capital is deeply rooted in the belief that pioneering medical technologies can simultaneously improve healthcare and generate substantial returns.

42CAP, established in 2016 and based in Munich, Germany, is a venture capital firm that focuses on seed-stage investments in B2B technology startups across Europe. The firm is notable for its emphasis on data-driven and SaaS companies, with a strong interest in applications of artificial intelligence and machine learning. Their portfolio includes notable startups like Adverity, a marketing analytics platform, and OnTruck, a real-time marketplace for truck deliveries. 42CAP typically invests between €0.5 million and €1.5 million per company and aims to back ventures that can scale globally from a European base. 42CAP's strategic approach involves partnering with visionary founders to drive technological innovations in B2B sectors. They seek companies that enable organizational agility and efficiency, particularly in fields such as big data and IoT. Their latest fund, totaling €50 million, is set to support approximately 20 startups, expanding on the success of their initial investments. The team behind 42CAP includes experienced entrepreneurs and investors like Alex Meyer and Thomas Wilke, who previously built successful companies such as eCircle and Relayr. This diverse and experienced team is integral to their hands-on approach in supporting portfolio companies from early stages to market leadership.

468 Capital is a venture capital firm headquartered in Berlin and San Francisco, specializing in early-stage investments across various high-tech sectors. Founded in 2020 by Ludwig Ensthaler and Florian Leibert, the firm focuses on technologies that redefine markets, particularly in automation, electrification, software, and consumer/prosumer sectors. Notable investments in their portfolio include companies like Rapid Robotics, Worldcoin, and Superchat, showcasing their interest in innovative and transformative technologies. 468 Capital has made a total of 164 investments, with recent notable exits including natif.ai and Talentspace. The firm's investment strategy is thematic and high-conviction, emphasizing versatility, global reach, and big thinking. This approach is backed by a strong network of founders, operators, and investors, helping portfolio companies grow and achieve significant milestones, including public listings. Their team combines technological expertise with deep market knowledge, enabling them to make agile investment decisions and provide substantial support to their portfolio companies. With offices in Berlin, Madrid, and San Francisco, 468 Capital is well-positioned to support startups in raising global capital, growing teams, and launching products internationally​.

4BIO Capital is a London-based venture capital firm specializing in advanced therapies, particularly in areas like gene therapy, cell therapy, RNA-based treatments, and the microbiome. The firm is focused on addressing high unmet medical and social needs through early-stage investments in innovative life sciences companies. Founded by a team of experienced academics, physician-scientists, and industry executives, 4BIO Capital has built a strong reputation for its deep expertise in the rapidly evolving field of advanced therapies. The firm’s strategy involves not only backing early-stage startups but also creating new companies by leveraging cutting-edge research from academic institutions across Europe and the U.K. 4BIO Capital recently raised $50 million for its second advanced therapy VC fund, with plans to increase this to $150 million. This fund is dedicated to expanding the use of advanced therapies beyond rare diseases to treat more prevalent conditions like diabetes and rheumatoid arthritis. The firm has a global investment focus, with no geographical restrictions, though it emphasizes the untapped potential within U.K. institutions. The team at 4BIO includes managing partners Dmitry Kuzmin and Andrew Kozlov, who bring a wealth of knowledge and experience in life sciences and venture investing, helping to drive the firm’s mission of bringing transformative therapies to market​.

Founded in 2012, 50 Partners is a Paris-based venture capital firm and startup accelerator. It stands out for its robust support of early-stage companies in the tech, impact, and healthtech sectors. Notable investments include Pixacare, Surge, Wakeo, and Albert. They have achieved successful exits with companies like SimpliField, ProcessOut, and TwicPics. 50 Partners primarily focuses on the French market but has also shown interest in broader European opportunities. Their investment strategy emphasizes early-stage funding, with an average round size of around $2 million. They typically make about seven investments per year and have been particularly active recently, with peak activity in 2022. The team at 50 Partners consists of experienced entrepreneurs and investors, including co-founders Jérôme Masurel, Christophe Berly, Laurent Letourmy, and Rolland Mor. These leaders bring diverse expertise across various industries and business models, providing valuable mentorship to their portfolio companies. For startups looking to engage with 50 Partners, it's crucial to demonstrate strong innovation and scalability potential. They prefer to work closely with founders who are transparent and collaborative, ensuring a good fit with their hands-on approach to nurturing growth.

500 Global, formerly known as 500 Startups, is a prominent venture capital firm with a robust global presence and over $2.4 billion in assets under management. Since its inception in 2010, it has invested in more than 2,800 companies across 80+ countries. Some of its most notable investments include Credit Karma, Twilio, Canva, Grab, Bukalapak, The RealReal, Talkdesk, Udemy, and Ipsy​​. 500 Global's industry focus spans various sectors, with significant investments in consumer services, software-as-a-service (SaaS), fintech, and media​ (Proptech Zone)​. Its geographic focus is truly global, with operations in major innovation hubs such as Silicon Valley, New York, London, Singapore, and Mexico City, as well as emerging markets like Lagos, Jakarta, and Riyadh​​. The fund's strategy involves early-stage investments, providing seed capital along with comprehensive support through its Seed Accelerator Programs. These programs emphasize digital marketing, customer acquisition, lean startup methodologies, and fundraising strategies. 500 Global prefers to invest in companies with high growth potential and innovative business models​. Typically, 500 Global invests an average of $150,000 to $250,000 in initial seed rounds and often leads these rounds. The firm is known for its hands-on approach, leveraging its extensive network of mentors, industry experts, and alumni to support portfolio companies. Recently, 500 Global has been active in launching thematic funds targeting specific industries and regions, further expanding its investment reach​​. The leadership team includes Christine Tsai, the CEO and Founding Partner, who has steered the firm’s growth and global expansion. 500 Global's diverse team of over 100 members spans more than 30 countries, bringing a wealth of experience as entrepreneurs, investors, and operators from leading tech companies​.

574 Invest is the corporate venture capital arm of the SNCF Group, France’s national railway company. Established in 2019 and headquartered in Paris, the fund focuses on early to growth-stage investments in sectors like mobility, Industry 4.0, and climate tech. The fund’s primary mission is to drive innovation in the transportation and industrial sectors, aligning with SNCF’s broader objectives of enhancing sustainable mobility solutions. 574 Invest mainly targets investments in France and Europe, seeking companies that are pioneering new technologies in areas such as micro-mobility, mass transit, and green mobility. The fund leverages SNCF’s extensive industry expertise and resources to offer more than just capital, providing strategic partnerships and access to the company’s vast commercial network. This allows portfolio companies to collaborate closely with SNCF’s various business units, accelerating the development and adoption of their technologies. Some of 574 Invest's notable investments include Electra, which focuses on energy services, and XXII, a company specializing in computer vision technologies. The fund also actively promotes the integration of Industry 4.0 technologies, such as IoT and predictive maintenance, within the transportation sector. 574 Invest's approach is highly strategic, aiming to foster long-term partnerships that can enhance both the SNCF Group's operations and the broader mobility ecosystem.

7percent Ventures is a London-based venture capital firm founded in 2014 by ex-founders Andrew Scott and Andrew Gault. Specializing in early-stage investments, the firm focuses on deep-tech startups with transformative potential, often referred to as "moonshot" companies. 7percent Ventures targets industries such as AI, quantum computing, AR/VR, spacetech, and future computing. Their investment philosophy is driven by supporting highly ambitious projects that aim to disrupt entire industries. The firm typically invests at pre-seed, seed, and Series A stages, with a typical investment range of €100,000 to €1.5 million. Notable companies in their portfolio include Oculus VR, which was acquired by Meta, and Universal Quantum, a pioneer in quantum computing. They also have a strong transatlantic reach, with investments spanning both the U.K. and the U.S., particularly in Silicon Valley. 7percent Ventures’ partners bring over 150 years of combined experience as entrepreneurs and investors, offering not just capital but also strategic mentorship, leveraging their extensive networks to help startups scale. The firm emphasizes the importance of transformative innovation and risk-taking in achieving sector-defining success​.

83North is a global venture capital firm with over $2.2 billion in assets under management. Founded in 2006, the firm invests across various stages and sectors, with a focus on supporting exceptional entrepreneurs in building global category-leading companies. The firm operates with a philosophy that emphasizes deep involvement with portfolio companies, long-term relationships, and a lean operational structure, maintained by its four equal partners: Laurel Bowden, Gil Goren, Yoram Snir, and Arnon Dinur. 83North has a significant presence in the US, Europe, and Israel, investing in industries ranging from software and IT to fintech, healthcare, and consumer technology. Notable investments include companies such as Mirakl, Payoneer, Paddle, and Snappy. The firm prides itself on having helped create 14 unicorns and achieving 32 successful exits out of nearly 90 investments. Their investment strategy is grounded in the belief that venture capital is not a scalable business, but rather one that benefits from a focused, hands-on approach. This strategy allows 83North to maintain quick, transparent processes and build a high level of trust with their entrepreneurs.

8X Ventures is a deep-tech-focused venture capital firm established in 2021, with offices in Dubai and significant operations in India. The firm primarily invests in early-stage startups that are driving innovation across sectors like biotechnology, Industry 4.0, clean technology, and advanced computing. 8X Ventures has a strong emphasis on supporting startups that have the potential to disrupt industries and create sustainable value through groundbreaking technologies. In 2023, 8X Ventures expanded its presence in India by opening offices in Delhi and the IIT Research Park in Chennai, reinforcing its commitment to the Indian deep-tech ecosystem. The firm’s investment strategy involves thorough research and a long-term partnership approach, where they don’t just invest but actively collaborate with startups to help them scale. The firm’s portfolio includes around 18 companies, with most of its investments concentrated in India and Southeast Asia. Notable recent investments include Pantherun and XYMA Analytics in India, focusing on high-tech sectors like semiconductors and environmental technology. 8X Ventures recently launched its second fund, a SEBI-registered CAT II fund, with a corpus of ₹200 crore aimed at supporting 18-20 startups in India’s deep-tech sector. The firm’s experienced team, led by Managing Partner Chirag Gupta, is dedicated to identifying and nurturing startups that can lead the next wave of technological innovation​.

A Plus Finance, founded in 1998 and headquartered in Paris, is a private equity firm specializing in the management of Common Investment Funds for Innovation (FCPI) and Proximity Investment Funds (FIP). The firm focuses on investing in innovative sectors such as IT, media, security, real estate, audiovisual, industrial, and environmental fields. A Plus Finance's portfolio is diverse, including notable investments in companies like Biotulin, Industrie Ofen Service, and Anotherway. The firm is known for its significant exits, including companies like Adeunis RF, Extruflex, and Intequedis. A Plus Finance typically participates in investment rounds with other co-investors, contributing to the growth and expansion of its portfolio companies. Led by key figures such as co-founder Niels Court-Payen, managing director Fabrice Imbault, and senior partner Hervé Legoupil, the firm leverages its extensive industry expertise to support the development and scaling of innovative businesses. Their investment strategy focuses on sectors that promise high growth potential and transformative impact, ensuring a robust and dynamic portfolio.

A Partners Capital is a global outsourced CIO (Chief Investment Officer) firm that provides tailored investment solutions to endowments, foundations, private clients, and institutions. Established in 2001, the firm is headquartered in London with additional offices in Boston, San Francisco, Singapore, Paris, and Hong Kong​. A Partners Capital focuses on alternative investments, including private equity, real estate, and hedge funds, seeking to deliver superior long-term returns through a rigorous, research-driven approach. Their investment philosophy emphasizes diversification, sustainability, and long-term value creation, utilizing their extensive global network and deep industry expertise. The firm provides clients with bespoke investment strategies that are aligned with their financial objectives and risk tolerance. A Partners Capital also manages private market mandates, offering opportunities in co-investments and direct investments across multiple sectors​. With a commitment to transparency and strong governance, A Partners Capital builds enduring partnerships with clients, helping them navigate complex market environments while maximizing returns.

AB Health Ventures, now operating under the name Cencora Ventures following AmerisourceBergen's rebranding to Cencora, is a $150 million venture capital fund. The fund focuses on early to mid-stage healthcare startups worldwide, prioritizing areas such as the future of pharmacy and distribution, clinical development, and commercialization of pharmaceuticals, healthcare provider solutions, and animal health. The fund leverages AmerisourceBergen's extensive expertise and global footprint to add value to its portfolio companies. It supports startups in rapidly prototyping solutions, conducting pilot tests, and accelerating commercialization. Notable recent investments include partnerships with TrakCel and Annexus Health, both leaders in their respective fields of cellular orchestration and healthcare technology. AB Health Ventures collaborates with Touchdown Ventures to manage its operations, ensuring that the fund's strategic and financial goals are met efficiently. The initiative aims to foster innovation in healthcare, driven by the belief that bold ideas and cutting-edge technologies can significantly improve patient outcomes and streamline healthcare delivery.

Abacus Alpha, founded in 2006 and based in Germany, is a prominent investment firm specializing in medium-sized, technology-driven companies across various sectors, including industrial, trade, and services. The firm’s core focus is on fostering sustainable growth and innovation, with a particular emphasis on industries such as automation, cleantech, innovative materials, and advanced production processes. Abacus Alpha is committed to long-term partnerships, working closely with portfolio companies to drive strategic development while allowing management teams the autonomy to manage day-to-day operations. This hands-off approach is paired with a strong emphasis on collaboration, where the firm provides strategic support and resources to help companies achieve their full potential. Abacus Alpha believes in creating synergies within its portfolio, aiming to build a network of companies that can leverage each other's strengths to drive growth and innovation. The firm's investment philosophy is rooted in the belief that sustainable value is created through careful selection of opportunities, targeted expansion, and diversification. Abacus Alpha seeks out companies with strong market positions and the potential for significant growth, investing not just capital but also expertise to help them scale effectively. By focusing on long-term value creation rather than short-term gains, Abacus Alpha has built a reputation as a reliable and forward-thinking partner in the German and European investment landscape. The firm’s approach has made it a key player in driving technological advancement and economic growth within the sectors it targets.

Abingworth, founded in 1973, is a transatlantic life sciences investment firm with a robust portfolio and a strategic focus on turning innovative science into transformative medical treatments. With offices in London, Boston, and San Francisco, Abingworth has invested in over 179 companies, resulting in 73 IPOs and 46 M&As. The firm operates across three main investment stages: seed and early-stage, development stage, and clinical co-development, and typically invests between $500,000 to $2 million in initial rounds, supporting portfolio companies through subsequent funding stages. Notable investments include Adaptate Biotherapeutics, Jasper, and Tizona Therapeutics. Abingworth's team, led by Managing Partners Tim Haines and Kurt von Emster, brings decades of experience in life sciences and venture capital. The firm is deeply embedded in key biotech hubs, facilitating productive interactions with entrepreneurs and access to top-tier scientific talent. The firm emphasizes long-term partnerships, providing not just capital but also strategic guidance in areas such as clinical development, regulatory approval, and commercialization. Abingworth's recent integration with Carlyle Group underscores its commitment to expanding its impact in the global healthcare investment ecosystem. Startups seeking investment from Abingworth should have groundbreaking science with the potential to materially improve patient outcomes. The firm values deep industry expertise, strong leadership, and a clear path to transformative impact.

ABN AMRO Ventures, the corporate venture arm of ABN AMRO Bank, operates with €150 million under management, focusing on fintech, regtech, and sustainability-oriented tech solutions. Their investments emphasize scaling startups that bolster financial services through AI, blockchain, data analytics, and innovative SaaS models. With a strategic geographic focus on Europe, they selectively branch out to North America and Israel. Their strategy aims to bridge the banking ecosystem with cutting-edge solutions, preferring Series A and later-stage rounds with investments ranging from €2 to €15 million. ABN AMRO Ventures often co-invests but does not always lead rounds, positioning itself as a value-added participant that extends industry insights and networking opportunities. The fund boasts a strong portfolio, including prominent names like Tink, Quantexa, and solar finance enabler Laka. They prioritize partnerships that align with the bank's broader objectives of innovation and sustainability. The team, steered by Managing Director Hugo Bongers and a group of seasoned financial and tech experts based in Amsterdam, emphasizes accessible communication with founders and appreciates clear, data-driven pitches. Startups are advised to demonstrate robust market potential, scalable technology, and strategic alignment with banking needs to capture their interest. ABN AMRO Ventures actively engages in fostering innovation hubs and prefers targeted, well-researched approaches when founders seek to initiate contact.

Acadian Ventures is an early-stage VC firm that focuses on the future of work, helping to build technologies that make work better, more equitable, and productive. Founded in 2019 by Jason Corsello, Acadian Ventures targets pre-seed, seed, and early Series A companies globally, with an emphasis on work tech, particularly in areas like intelligent work applications, work infrastructure, and new regulatory and compliance solutions. The firm typically invests between $500K to $1M, often co-investing alongside other VCs, and prefers to "fast follow" rather than lead rounds. Their hands-on approach and deep industry expertise have garnered them a high reputation among founders, with portfolio companies such as TechWolf and Compa praising their value as advisors. Anchored by notable LPs like ServiceNow Ventures, Acadian recently closed its second fund, a $30M commitment, nearly tripling their assets under management. They pride themselves on being highly engaged investors, often joining company boards as observers to support founders​.

Accel is a renowned venture capital firm known for its strategic investments across various stages and sectors. Founded in 1983, Accel has played a pivotal role in the success of numerous high-profile companies. Some of its most notable investments include Facebook, Dropbox, Spotify, and Slack, showcasing its strength in identifying and backing transformative technology companies early on. The firm's investment strategy focuses on seed and Series A funding, ensuring deep engagement with startups from their inception. Accel emphasizes a collaborative approach, providing not just capital but also mentorship and strategic support to help entrepreneurs build market-defining businesses. This hands-on involvement has led Accel to lead investments in over 70% of its portfolio companies​. Accel operates globally, with key offices in Silicon Valley, London, and Bangalore, enabling it to tap into entrepreneurial talent worldwide. The firm has recently closed on several funds totaling $3.05 billion, aimed at supporting early-stage startups and growth rounds for more mature companies​​. In 2023, Accel made significant investments in companies like Blackpoint Cyber, Headway, and Cyera, reflecting its commitment to diverse sectors such as cybersecurity, mental health, and data protection​​. This broad sector focus, combined with a global investment perspective, positions Accel as a key player in the venture capital landscape, continuously driving innovation and supporting exceptional entrepreneurs around the world.

Accion Venture Lab is an early-stage venture fund focused on empowering inclusive fintech startups that serve underserved and low-income populations globally. Established as part of Accion, a nonprofit dedicated to financial inclusion, Venture Lab provides seed-first capital paired with extensive strategic and operational support to help startups scale and overcome early challenges. Their diverse portfolio features innovative companies like Apollo Agriculture, which offers tech-driven financing to smallholder farmers in Kenya and Zambia, and Bababos, an Indonesian platform that supports small-scale manufacturers with raw materials and financing solutions. With a geographic reach that spans Latin America, the Caribbean, sub-Saharan Africa, the Middle East, North Africa, Southeast Asia, and even parts of the U.S., Accion Venture Lab's commitment is global. The fund targets industries such as digital lending, insurtech, personal financial management, and MSME-focused solutions, identifying startups with a mission to address systemic barriers to financial access. Their strategy is unique in that they prefer being the first institutional investor, ensuring startups receive not just capital but high-touch mentorship and strategic guidance. In 2019, Accion Venture Lab boosted its support efforts by launching a $23 million fund aimed at deepening their investment into inclusive fintech. Their approach prioritizes not only financial backing but also leveraging their deep-rooted expertise in financial inclusion to provide hands-on operational assistance. The team is led by seasoned Managing Partners Amee Parbhoo and Rahil Rangwala, who bring years of experience in fintech, impact investing, and scaling social enterprises. Founders looking for support from Venture Lab should demonstrate impactful, scalable solutions with clear pathways to financial inclusion.

ACE & Company, founded in 2005 and headquartered in Geneva, is a global investment group specializing in private equity and venture capital. The firm manages over $1.7 billion in assets across secondaries, buyouts, and ventures. With additional offices in London, New York, and Cairo, ACE & Company leverages a global network to source and manage investments. Notable investments include WiTricity, a company developing wireless charging technology, and Verto, a financial technology startup. The firm has a track record of successful exits, such as MoneyHero Group and Slauth.io. ACE & Company's investment strategy focuses on diversification and risk management, adjusting investment exposure based on the development stage of the companies. They aim to create long-term value through strategic support and capital allocation. Recently, they launched a €150 million fund targeting early-growth stage tech companies with a Swiss influence, particularly in climate tech, deeptech, fintech, and software​.

Ace Management Partners is a technology-driven investment firm specializing in high-potential pre-IPO companies across industries like AI, FinTech, and other disruptive technologies. Their thematic funds reflect a commitment to identifying transformative opportunities globally, with a focus on markets showing rapid innovation and growth. They prioritize transparency by integrating advanced technology and real-time data to provide investors with unparalleled insights and clarity in decision-making. Their strategy is bolstered by partnerships with market leaders who collectively have experience exceeding $30 billion in private company transactions. While their specific average check size isn’t publicly disclosed, they emphasize operational excellence, suggesting a proactive, well-calibrated investment approach. The team comprises experts passionate about innovation and fostering strategic partnerships, combining decades of private equity and venture capital expertise. With a strong base in New York, they leverage global market insights and local expertise to deliver exceptional results in the evolving pre-IPO landscape.

ACME Capital is a prominent venture capital firm based in San Francisco, specializing in early-stage investments in disruptive technologies and innovative business models. Founded in 2013 by Hany Nada, Shervin Pishevar, and Scott Stanford, the firm focuses on sectors such as healthcare, financial services, and space exploration. Their notable investments include high-profile companies like Uber, Slack, and DraftKings, demonstrating a knack for identifying and nurturing industry leaders. ACME Capital's investment strategy is centered on supporting visionary founders who are tackling large-scale challenges with groundbreaking solutions. They emphasize platform shifts and technology breakthroughs that promise significant societal benefits. The firm typically leads funding rounds and provides not just capital, but also strategic guidance and operational support to help startups scale effectively. Geographically, ACME Capital has a strong focus on the United States, but their portfolio also includes companies with a global reach. Their commitment to diversity and inclusion is reflected in their investment choices, with a significant portion of their portfolio companies led by underrepresented founders. The team at ACME Capital includes experienced partners like Brian Yee and Alexander Fayette, who bring a wealth of expertise and a hands-on approach to their investment process. Entrepreneurs looking to engage with ACME Capital are encouraged to present bold, transformative ideas that have the potential to disrupt massive markets and drive significant impact.

Acrobator Ventures is an Amsterdam-based VC fund with a focus on early-stage investments, particularly in the Dutch, Baltic, and CEE regions. Founded in 2019 by Bas Godska and Joachim Laqueur, the firm is known for its strong emphasis on B2B SaaS, AI/ML, and data-driven startups. Acrobator’s strategy is distinctive, offering continuous support from pre-seed through IPO. They typically write checks ranging from $200k to $1.25 million and often lead investment rounds. The fund's portfolio includes notable companies like Glovo, Taxify, Pipedrive, and Planet42. Acrobator Ventures places a strong emphasis on bridging Eastern European startups with Western markets, leveraging their deep industry connections and market access. Key team members include Bas Godska, who has a strong background in marketing, and Mike Reiner, who focuses on scaling and go-to-market strategies. The team is split across Amsterdam, Kyiv, and Tbilisi, emphasizing their regional expertise. Acrobator prefers a hands-on approach, building long-term relationships with founders, which has contributed to successful investments like Respeecher and Let’s Enhance. Their flexible fund structure allows investors to opt into later rounds without being penalized, aligning the interests of all parties involved.

ACT Venture Capital, based in Dublin, Ireland, is an early-stage venture capital firm founded in 1994. The firm focuses on investing in high-potential technology companies across sectors such as AI, machine learning, enterprise software, deep tech, healthcare, and energy & climate. ACT has completed over 70 investments and manages around €627 million across multiple funds. Notable companies in ACT Venture Capital's portfolio include Cubic Telecom, a global connectivity management company; Ekco, a leading provider of cloud services; and Deciphex, which develops software solutions for digital pathology. The firm also backs companies like Gridbeyond, which focuses on intelligent energy management systems, and Provizio, an automotive safety technology company. ACT Venture Capital recently launched its sixth fund, ACT VI, with an initial close of €140 million, aiming to invest in 35 companies across its targeted sectors. This fund supports startups from seed to expansion stages, with the capacity to invest up to €10 million per company. The firm has a strong track record of successful exits, including the acquisition of SilverCloud Health by Amwell, Decawave by Qorvo, and Corvil by Pico. The leadership team at ACT includes John Flynn, Debbie Rennick, and John O’Sullivan, who bring extensive experience and expertise to the firm, supporting their portfolio companies through strategic guidance and robust networks.

ACT Venture Partners is an Amsterdam-based venture capital firm focusing on early-stage investments in deep-tech and enabling technologies across Europe, with additional strong ties to the Turkish market. They target sectors such as AI, IoT, data analytics, and healthcare, investing primarily during Seed and Series A rounds. ACT aims to back technically strong founders who are pioneering disruptive, market-transforming solutions. Some notable companies in their portfolio include Picus Security, Carbon Health, Eatron, and Nextmol. The firm typically leads seed rounds with checks up to €1 million, often continuing to support portfolio companies in subsequent funding rounds. Their investment strategy emphasizes hands-on collaboration, providing not only financial backing but also mentorship, networking, and strategic advice to help startups achieve critical product-market fit and scale. The core team comprises experienced professionals with backgrounds in engineering, finance, and entrepreneurship. Key figures include managing partners Erhan Kılıçözlü and Okan Kara, who bring decades of experience in tech transfer, venture capital, and innovation management, contributing to ACT's reputation as a value-adding partner for startups. ACT's approach involves close engagement from initial funding through to growth stages, leveraging their extensive network across Europe and beyond.

Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GlaxoSmithKline (GSK) in 2013. The firm focuses on advancing bioelectronic medicines and enabling technologies. APVC is headquartered in Cambridge, Massachusetts, with additional offices in Scotts Valley, California. APVC invests in companies that leverage advances in hardware, computing, and material science to regulate neural or cellular activity, aiming to treat a range of chronic diseases. Notable portfolio companies include Cala Health, which develops non-invasive neuromodulation therapies for conditions like essential tremor; CVRx, known for its FDA-approved BAROSTIM NEO therapy for heart failure; and Neuspera Medical, which is developing minimally invasive neuromodulation therapies for overactive bladder. The firm takes a hands-on role on the boards of startups, providing strategic guidance and support. APVC has made 25 investments to date, with recent notable investments in Exo, which offers AI-enabled handheld ultrasound imaging, and MicroTransponder, which focuses on therapies for neurological conditions. APVC's investment approach emphasizes diversity and inclusion within the healthcare and entrepreneurial communities. The leadership team includes Imran Eba and Juan-Pablo Mas, who bring extensive experience in venture capital and biotechnology investments.

Activate Capital is a San Francisco-based venture capital firm established in 2017 with a focus on investing in high-growth companies that are transforming industries through technology. The firm specializes in sectors such as climate tech, energy management, infrastructure technology, and IoT, aiming to foster a sustainable, resilient global economy. Activate Capital primarily targets Series B, C, and D funding rounds, providing capital to companies at a critical growth phase. The firm has built a diverse portfolio of innovative companies including Voltus, Element Analytics, StreetLight Data, and Optimal Dynamics, all of which leverage advanced technologies to solve environmental and economic challenges. Activate's focus areas span clean energy, smart cities, AI, and machine learning, aligning with its mission to support companies that are redefining how industries function while addressing climate change. With more than $1.5 billion in capital raised, Activate Capital is led by a team of seasoned investors, including Managing Partners Anup Jacob and David Lincoln, who have decades of experience in energy and infrastructure. Their investment approach emphasizes long-term partnerships, working closely with founders to build category-defining companies. Recent investments include Altana AI, a company focused on AI-driven logistics, and Sympower, which specializes in renewable energy and smart cities. Activate Capital’s commitment to sustainability-driven innovation positions it as a key player in the growing climate tech and infrastructure investment space, helping reshape the industrial landscape for a greener future.

Ada Ventures is a London-based venture capital firm focused on supporting early-stage startups with a particular emphasis on diversity and inclusion. Founded by Check Warner and Matt Penneycard, Ada Ventures aims to back founders who are often overlooked and underfunded, targeting sectors like climate equity, economic empowerment, and healthy aging​. The firm typically makes initial investments of around £500,000 and has developed innovative deal-sourcing methods, including a scout network and angel investment programs to reach underrepresented communities. This approach has led to successful investments in companies such as Huboo, Organize, and MOONHUB. Ada Ventures' portfolio from its first fund has raised an aggregate of £100 million in additional funding from prominent firms like GV and Index Ventures. Ada Ventures recently launched its second fund, raising £41 million in the first close, demonstrating strong support from the investor community and its commitment to creating a more inclusive venture capital landscape.

Adara Ventures, founded in 2005 and headquartered in Madrid, Spain, specializes in early-stage investments in deep tech companies, focusing on sectors like cybersecurity, data and applications, infrastructure, DevOps, components, and digital health. Managing around €200 million in assets, Adara has invested in 85 companies. Their portfolio includes notable companies such as Seedtag, Scalefast, and AlienVault. Seedtag, a leader in Contextual AI for the AdTech industry, is one of their standout investments. Adara led Seedtag's initial €1.5 million round and has supported the company through its significant growth and recent €250 million funding round led by Advent International. Adara has seen several successful exits, including AT&T Cybersecurity and PlayGiga, showcasing their ability to identify and nurture high-potential startups. They typically invest in seed, Series A, and Series B rounds, with check sizes ranging from $500,000 to $3 million. The Adara team includes experienced professionals like Managing Partners Alberto Gómez and Nicolas Goulet, and Partner Alberto Echeverri, who bring extensive expertise to support their portfolio companies' growth and success. Adara Ventures continues to play a significant role in the European venture capital landscape, particularly in Spain and Western Europe.

AdBio Partners, previously known as Advent France Biotechnology, is a Paris-based venture capital firm specializing in early-stage investments within the life sciences sector. Established in 2016, AdBio Partners focuses on identifying and nurturing promising startups across Europe, particularly in France, Belgium, Spain, and Ireland. Their investment strategy is centered on therapeutics, supporting innovative biotech projects with high potential to address unmet medical needs. The firm is deeply integrated into the European life sciences ecosystem, collaborating closely with research institutions and technology transfer offices to transform groundbreaking scientific discoveries into viable businesses. AdBio Partners also plays an active role in the development of its portfolio companies, often co-founding and providing hands-on operational support to ensure their growth and success. Led by an experienced team of professionals with extensive backgrounds in science, medicine, and entrepreneurship, AdBio Partners has successfully attracted international VC syndicates, further strengthening its portfolio. Some notable companies backed by AdBio include DiogenX and ARTHEx Biotech.

Advent Life Sciences is a leading transatlantic venture capital firm that focuses on investing in early and mid-stage life sciences companies. The firm emphasizes innovation in areas such as new drug discovery, medical technology, enabling technologies, and vaccines. Advent Life Sciences takes a hands-on approach, working closely with management teams to bring their visions to life, aiming for superior financial returns by bringing innovative solutions to patients. Advent Life Sciences has a strong portfolio of companies that have brought significant advancements in healthcare. Notable investments include AviadoBio, which focuses on gene therapy for neurodegenerative disorders, and Amphista Therapeutics, which develops protein degradation technologies for targeted cancer therapies. The firm also backs companies like Cellnovo, which created a micro insulin pump with connectivity, and Centessa Pharmaceuticals, a novel asset-centric pharmaceutical company. The firm is known for its experienced team of professionals, combining deep technical, commercial, and financial expertise. Key team members include Don Drakeman, Majid Kazmi, and Katrine Bosley, who bring substantial industry knowledge and strategic guidance to their portfolio companies. Advent Life Sciences is committed to supporting the growth of life sciences innovations, helping companies navigate the complex journey from scientific discovery to market-ready products.

AENU is a venture capital fund that’s making waves by focusing on early-stage climate tech companies, aligning profitability with environmental and social impact. Based in Europe, AENU primarily invests in startups that tackle the climate crisis through innovations in energy transition, carbon economy, and sustainability. Their portfolio includes impactful companies such as Alcemy, Monta, Ocell, Trawa, and Hometree, which work on solutions ranging from low-carbon cement to intelligent energy management. With a geographic focus on Europe, especially the DACH region, Nordics, and the UK, AENU targets Seed and Series A investments, typically writing checks between €1-4 million. They often co-lead or lead rounds and always aim for board representation to ensure a strategic partnership. Their innovative Impact-as-a-Service (IaaS) offering helps portfolio companies scale while maintaining strong environmental, social, and governance (ESG) standards. Founded by Fabian Heilemann and Ferry Heilemann, AENU boasts a team of seasoned entrepreneurs and investors with a proven track record of scaling ventures. The fund is committed to systemic transformation within venture capital, pushing for stakeholder alignment and equitable growth. Startups looking to partner with AENU should expect a research-driven, high-impact approach, where both financial returns and climate outcomes are equally prioritized​.

Aera VC is a venture capital firm focused on investing in climate tech and frontier technologies that aim to advance humanity and create a sustainable future. Founded in 2016 by Derek Handley and Nick Winstone, Aera VC operates from New York, Singapore, and New Zealand. The firm invests globally, targeting early-stage companies that drive transformational change across various industries. Notable investments include Solugen, which transforms chemicals using plant-based processes, and Twelve, a company that recycles CO₂ into cost-competitive chemicals and fuels. Other significant investments are Shiok Meats, a Singapore-based company developing cell-based seafood, and Carbon Chain, which offers solutions to reduce greenhouse gas emissions in supply chains. Aera VC also supports startups like AstroForge, focused on space technology, and Paloma Health, an online medical practice specializing in hypothyroidism. Aera VC recently raised $42 million in the first close of its new climate-focused fund, which will be used to back up to 30 new seed investments over the next two years. The firm aims to support breakthrough technologies that can significantly reduce the world's carbon footprint and advance sustainable practices across various sectors.

Aescuvest is a prominent pan-European venture capital firm that specializes in health technology. Headquartered in Frankfurt, Germany, Aescuvest collaborates with EIT Health, giving it exclusive access to some of the most promising healthtech startups across Europe. The firm focuses on early to late-stage ventures, investing in areas such as remote monitoring, diagnostics, personalized medicine, and AI in healthcare. Notable investments include startups like Neteera and Caresyntax, showcasing their commitment to advancing healthcare technology. Aescuvest's strategy emphasizes a rigorous selection process and thorough due diligence to ensure exponential growth potential for their investments. They prefer to lead funding rounds and remain actively involved in the growth of their portfolio companies. Aescuvest targets investments primarily within Europe and Israel, fostering a network of healthcare technology-driven investors, including business angels and corporate investors. The fund's typical investment size averages around $2.85 million per round. For startups seeking investment, Aescuvest values innovation that promises substantial improvements in patient outcomes and healthcare delivery. Their approach to building an investment funnel involves leveraging partnerships and a deep understanding of the healthtech sector to identify high-impact opportunities. Key team members include experts deeply rooted in the healthcare industry, such as Helmut Nanz, whose experience and strategic insight drive Aescuvest's mission to transform healthcare through technology.

Afore Capital is a San Francisco-based venture capital firm specializing in pre-seed stage investments. Founded in 2016, Afore Capital manages a $300 million fund and typically invests $500,000 to $2 million in early-stage companies that are pre-traction and pre-revenue. The firm focuses on identifying high-potential startups and helping them rapidly scale towards Series A funding rounds. Afore Capital’s diverse portfolio includes companies across sectors such as SaaS, fintech, healthcare, consumer, and enterprise technology. Notable investments include Neo Financial, a digital bank; BetterUp, a platform for professional coaching; and Curefit, a provider of digital and offline fitness services. The firm has a strong track record, with several successful exits and notable co-investments alongside top venture funds like Andreessen Horowitz and Accel​.

AE.no is a prominent force in Norway's aquaculture sector, focusing on sustainable innovations that enhance the efficiency and environmental stewardship of fish farming. As Norway remains a global leader in seafood production, AE.no plays a critical role in supporting the industry’s evolution by developing advanced technologies aimed at minimizing the ecological impact of aquaculture practices. The company’s initiatives are closely aligned with both national and global sustainability objectives, reflecting its commitment to promoting responsible growth within the industry. In addition to its work in traditional fish farming, AE.no is exploring new frontiers within the aquaculture value chain, including emerging sectors like seaweed farming and the development of sustainable feed alternatives. This approach not only helps diversify Norway’s aquaculture offerings but also contributes to the broader goals of environmental sustainability and food security. AE.no collaborates with a range of stakeholders, including government agencies, research institutions, and international organizations, to ensure that its practices are at the forefront of industry standards. The company’s efforts are vital in helping Norway maintain its position as a world leader in seafood production while also addressing the growing global demand for sustainable aquaculture products. By driving innovation and fostering partnerships, AE.no is paving the way for the future of aquaculture, ensuring that it remains a viable and environmentally sound industry for generations to come.

Aglaé Ventures is a global technology-focused investment firm established in 2017, with headquarters in Paris and offices in New York and San Francisco. The firm is backed by Agache (formerly Groupe Arnault), the principal investment vehicle of Bernard Arnault, the controlling shareholder of LVMH. Aglaé Ventures invests in fast-growing tech companies at all stages, from seed to pre-IPO rounds, with investment sizes ranging from €100K to €100MM. Notable investments by Aglaé Ventures include high-profile companies such as Airbnb, Slack, Spotify, and Lyft. The firm is sector-agnostic but concentrates on asset-light and scalable business models, particularly in marketplaces, SaaS, content platforms, consumer apps, and digitally native vertical brands. Aglaé Ventures emphasizes a long-term investment approach, providing flexible and enduring capital while supporting portfolio companies with expertise in growth management, brand building, digital marketing, and global expansion strategies. The firm also leverages its extensive network, including access to the LVMH ecosystem, to accelerate the growth of its portfolio companies. The team at Aglaé Ventures includes experienced investors and entrepreneurs like Miyuki Matsumoto, Managing Partner and Head of US Investments, and co-founders Cyril Guenoun and Antoine Loison. The firm prides itself on its simple investment terms and quick decision-making processes, making it an attractive partner for ambitious founders​.

Aglaia Oncology Funds is a Dutch venture capital firm specializing in early-stage investments in oncology. Founded in 2004, the firm focuses on groundbreaking technologies that have the potential to transform cancer diagnosis and treatment. Aglaia actively collaborates with scientists and management teams to translate high-potential research into commercially and clinically successful products. Aglaia's portfolio includes notable companies such as Cristal Therapeutics, Inthera Bioscience, Macrophage Pharma, Mimetas, Modra Pharmaceuticals, and Sapreme Technologies. The firm has also seen successful exits with companies like Merus and Synthon. The team at Aglaia is led by partners Eric van der Putten, Karl Rothweiler, Mark Krul, and supported by a strong advisory board comprising experts in oncology and biotech, including Alan Barge, Sjoerd van der Burg, and Kees Melief. This team brings deep expertise in cancer research and drug development, ensuring that their portfolio companies receive comprehensive strategic support. Aglaia Oncology Funds emphasizes impact investing, aiming to generate both financial and social returns by advancing innovative cancer treatments.

AgriTech Hub is a pioneering venture capital fund based in Warsaw, Poland, dedicated to transforming the agricultural and food technology sectors across Central and Eastern Europe. Launched as the region's first VC fund with a specific focus on agri-tech, AgriTech Hub invests in early-stage companies that leverage cutting-edge technology and data analytics to address critical challenges in agriculture, food production, and sustainability. The fund's investment strategy targets innovative solutions in four primary areas: foodtech, waste-tech, bioenergy, and advanced sensors. In foodtech, AgriTech Hub is particularly interested in novel processing techniques, such as osmotic drying and food disinfection methods, which enhance product quality and safety. The waste-tech sector offers significant opportunities for managing food production waste and optimizing resource use, while the bioenergy focus supports projects that advance renewable energy through improved fermentation processes at biogas plants. Additionally, AgriTech Hub invests in IoT and advanced sensor technologies that improve agricultural efficiency by monitoring critical environmental factors. AgriTech Hub typically invests between $250,000 and $5 million, supporting companies from their inception through to early growth stages. The fund's portfolio includes notable investments like Agrivi, a leading farm management software provider, and FitAdept, a personalized fitness platform. These investments reflect the fund's commitment to driving technological advancements that contribute to a more sustainable and efficient agricultural sector. By backing startups that address global food and energy challenges, AgriTech Hub aims to create impactful, long-term solutions that benefit both the environment and the economy.

Agronomics is a London-listed investment firm leading the charge in cellular agriculture, a field focused on producing agricultural products directly from cell cultures rather than through traditional farming. This approach holds promise in addressing critical issues like climate change, deforestation, and food insecurity. Agronomics invests in ventures aiming to disrupt animal husbandry and conventional food production, focusing on meat, dairy, leather, and other products derived through cutting-edge biotechnology, precision fermentation, and tissue engineering. Their portfolio includes over 20 companies, such as Meatable, a cultivated meat firm specializing in pork and beef, and BlueNalu, which is developing cell-based seafood products. These startups are pioneering solutions to replace conventional protein sources with more sustainable alternatives, reducing environmental impact and improving food security. Agronomics typically targets early-stage investments, leveraging its expertise to support companies through technological and regulatory challenges. The firm invests globally, with a particular focus on the rapidly growing precision fermentation and cellular agriculture sectors. Their goal is to not only provide capital but also help drive regulatory approvals and scalability for sustainable food production. Led by co-founders Jim Mellon and Denham Eke, Agronomics offers a unique blend of financial and scientific insight. Their active approach includes deep involvement in company growth strategies, particularly around impact and sustainability metrics. This positions Agronomics as a leader in shaping the future of food technology.